Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May;25(3):523-535.
doi: 10.1007/s10741-019-09873-3.

SERCA2a: a key protein in the Ca2+ cycle of the heart failure

Liu Zhihao  1   2 , Ni Jingyu  1   2 , Li Lan  1   2 , Sarhene Michael  1   2 , Guo Rui  1   2 , Bian Xiyun  3 , Liu Xiaozhi  3 , Fan Guanwei  4   5
Affiliations
Review

SERCA2a: a key protein in the Ca2+ cycle of the heart failure

Liu Zhihao et al. Heart Fail Rev. 2020 May.

Abstract

Calcium ion (Ca2+) cycle plays a crucial role in the contraction and relaxation of cardiomyocytes. The sarcoplasmic reticulum (SR) acts as an organelle for storing Ca2+, which mediated the release and re-uptake of Ca2+ during contraction and relaxation. Disorders of SR function lead to the dysfunction of Ca2+ cycle and myocardial cell function. The sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 2a (SERCA2a) acts as a subtype of SERCA expressed in the heart, which mediates the contraction of cardiomyocytes and Ca2+ in the cytoplasm to re-enter into the SR. The rate of uptake of Ca2+ by the SR determines the rate of myocardial relaxation. The regulation of SERCA2a activity controls the contractility and relaxation of the heart, affecting cardiac function. The expression and activity of SERCA2a are reduced in failing hearts. Gene therapy by increasing the expression of SERCA2a in the heart has been proven effective. In addition, SERCA2a is regulated by a variety of factors, including transmembrane micropeptides, protein kinases, and post-translational modifications (PTMs). In this review, we discuss the regulatory factors of SERCA2a and provide new insights into future treatments and the direction of heart failure research. In addition, gene therapy for SERCA2a has recently emerged as therapeutic option and hence will be discussed in this review.

Keywords: Gene therapy; PTM; SERCA2a; Transmembrane micropeptides.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Mol Biol. 2006 Apr 28;358(2):420-9 - PubMed
    1. Trends Neurosci. 2009 Nov;32(11):591-601 - PubMed
    1. Nat Rev Endocrinol. 2016 Jan;12(1):43-60 - PubMed
    1. Adv Mater. 2017 May;29(20): - PubMed
    1. JACC Heart Fail. 2014 Feb;2(1):84-92 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources